FDA Approves Monthly Dosing for Subcutaneous Amivantamab in EGFR-Mutated NSCLC
“The U.S. Food and Drug Administration has approved a once-monthly dosing schedule for frontline amivantamab and hyaluronidase-lpuj (Rybrevant Faspro), the subcutaneous formulation of the bispecific antibody, for adults with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The new dosing schedule applies to all of amivantamab’s previously approved indications.”
Immunotherapy Combo Fails to Improve Survival in Limited-Stage Small Cell Lung Cancer
“Adding atezolizumab (Tecentriq) to concurrent chemoradiation therapy (CRT) did not improve survival for patients with limited-stage small cell lung cancer (LS-SCLC), according to a recent clinical trial. However, experts say that the results add clarity to treatment sequencing questions and reinforce the current standard of care, despite the negative findings.”
ASCO Updates First-Line Treatment for Stage 4 EGFR Lung Cancer
“These new guidelines, published in the Journal of Clinical Oncology, provide a roadmap for using newer combination therapies as the first treatment for patients whose cancer has certain mutations, such as those in the EGFR gene. By incorporating the latest data from 13 clinical studies, the expert panel aims to help patients with cancer and their healthcare teams choose the most effective treatment options based on the unique genetic signature of their tumor.”
‘A breath of fresh air’: UW chair of surgery’s push for early detection of America’s deadliest cancer
“Lung cancer fatalities exceeded the combined fatalities from colon, breast, and prostate cancer in 2014. And in 2010, 65 to 80% of adults with cervical, breast, prostate, and colorectal cancer were up to date on screenings, but lung cancer was not screened at all. Without early detection, the majority of cases are caught in later stages, when the chance of survival is less than 10%.”
This new blood test could detect cancer before it shows up on scans
“A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNA nanotechnology, CRISPR, and quantum dots to generate a clear signal from just a few molecules. In lung cancer tests, it worked even in real patient serum samples. Researchers hope it could eventually power portable blood tests for cancer and other diseases.”
Mayo Clinic study identifies mechanism behind immunotherapy resistance in lung cancer
“PHOENIX — Mayo Clinic researchers and collaborators have identified a previously unrecognized way lung tumors weaken the immune system, helping explain why many patients do not respond to immunotherapy and pointing to a potential new approach to make those treatments more effective. The study, published in Cancer Immunology Research, focuses on regulatory T cells, immune cells that normally keep the immune system from becoming overactive.”
Can We Afford the New Era of Lung Cancer Survival?
“Partitioned survival modeling estimated OS 66.1 vs 57.8 months and PFS 40.2 vs 31.8 months for durvalumab vs placebo, with substantially higher total costs.”
Does Lung Cancer Screening Have a Psychological Impact?
“Recipients of low-dose computed tomography (LDCT) screening for lung cancer experienced increased psychological distress, which can contribute to diminished quality of life, according to results from a recent study.”
The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management
“Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of lung cancer, yet the heterogeneity in their efficacy and toxicity among different patients remains a significant clinical challenge. Obesity, as a global epidemic associated with chronic low-grade systemic inflammation and complex immunometabolic disturbances, has been identified as a crucial regulatory factor in cancer immunotherapy response. This review aims to systematically and deeply explore the intricate network of interactions between obesity, lung cancer, and immunotherapy.”
